Verona Pharma (LON:VRP)‘s stock had its “strong-buy” rating reiterated by investment analysts at N+1 Singer in a research report issued to clients and investors on Friday.

Other analysts also recently issued reports about the stock. reiterated a “buy” rating on shares of Verona Pharma in a report on Tuesday, November 7th. Jefferies Group reiterated a “buy” rating and issued a GBX 250 ($3.45) target price on shares of Verona Pharma in a report on Wednesday, November 8th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of GBX 130 ($1.80).

Shares of Verona Pharma (LON VRP) opened at GBX 145 ($2.00) on Friday. Verona Pharma has a fifty-two week low of GBX 100 ($1.38) and a fifty-two week high of GBX 189 ($2.61). The company has a market cap of $167.10 and a P/E ratio of -659.09.

Verona Pharma (LON:VRP) last released its earnings results on Tuesday, February 27th. The company reported GBX (23.40) (($0.32)) EPS for the quarter, topping analysts’ consensus estimates of GBX (26.10) (($0.36)) by GBX 2.70 ($0.04).

TRADEMARK VIOLATION WARNING: “N+1 Singer Reaffirms Strong-Buy Rating for Verona Pharma (VRP)” was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at

About Verona Pharma

Verona Pharma plc is a United Kingdom-based clinical-stage biopharmaceutical company. The principal activity of the Company is the development of drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. The Company’s product candidate, RPL554, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4 (PDE3 and PDE4) that acts as both a bronchodilator and an anti-inflammatory agent in a single compound.

Analyst Recommendations for Verona Pharma (LON:VRP)

Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with's FREE daily email newsletter.